Previous 10 | Next 10 |
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company has completed its Type C CMC meeting and has reached agreement with the U.S. Food and Drug Administration (FDA...
Gainers: Can-Fite BioPharma (NYSEMKT: CANF ) +38% . Outlook Therapeutics (NASDAQ: OTLK ) +30% . Del Frisco's Restaurant Group (NASDAQ: DFRG ) +27% . Orion Energy Systems (NASDAQ: OESX ) +23% . Sprint Corporation (NYSE: S ) +22% . ENDRA Life Sciences (NASDAQ: NDRA ) +18% . Sesen...
In February and March, I wrote about Sesen Bio’s ( SESN ) vast potential. Dr. Thomas Cannell, President & CEO, conducted a conference call on May 13 that presented information pretty much as I anticipated: directionally, timewise & strategically. Brief Background In our wo...
Sesen Bio, Inc. (SESN) Q1 2019 Results Earnings Conference Call May 13, 2019, 08:00 AM ET Company Participants Erin Clark - Executive Director, Strategic Planning & Investor Relations Thomas Cannell - President and Chief Executive Officer Dennis Kim - Chief Medical Officer ...
The following slide deck was published by Sesen Bio, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Amber Road (NYSE: AMBR ) +26% on being acquired by E2open. More news on: Amber Road, Inc., Onconova Therapeutics, Inc., Catalyst Pharmaceuticals, Inc., Stocks on the move, Read more ...
Sesen Bio ( SESN ) Q1 results : Revenues: $0; R&D Expense: $4.7M (+42.4%); SG&A: $3.1M (+55.0%); Net Loss: ($6.5M) (-62.5%); Loss Per Share: ($0.08) (+27.3%); Quick Assets: $42.4M (-15.9%). More news on: Sesen Bio, Inc., Healthcare stocks news, Earnings news and commentary, Stocks...
Sesen Bio (NASDAQ: SESN ): Q1 GAAP EPS of -$0.08 beats by $0.03 . More news on: Sesen Bio, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Company Announces Confirmed Meetings with the U.S. Food and Drug Administration in May and June 2019 to Review Registration Strategy for Vicinium ® Management to Host a Business Update Call Today at 8:00 a.m. EDT Sesen Bio (Nasdaq:SESN), a late-stage clinical company ...
Sesen Bio (SESN) is gearing up for a major event in the coming weeks. That's because it will host a conference call to both release earnings and give an update on one of its late-stage studies using Vicinium to treat patients with bladder cancer. This will take place on May 13, 2019, at 8:...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...